Bristol-Myers Squibb Company

Valuation Analysis

About the Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma fo

Bristol-Myers Squibb Company Stock at a Glance

Bristol-Myers Squibb Company (BMY) is currently trading at $57.13 with a market capitalization of $116.7B. The trailing P/E ratio stands at 16x, with a forward P/E of 9.27x. The 52-week range spans from $42.52 to $62.89; the current price is 9.2% below the yearly high. Year-over-year revenue growth stands at +2.6%. The net profit margin stands at 15.01%.

💰 Dividend

Bristol-Myers Squibb Company pays an annual dividend of $2.52 per share, representing a yield of 4.41%. The payout ratio stands at 70.03%.

📊 Analyst Rating

25 analysts rate Bristol-Myers Squibb Company (BMY) on consensus: Hold. The average price target is $63.08, implying +10.41% from the current price. Analyst price targets range from $40.00 to $75.00.

Bristol-Myers Squibb Company: The Investment Case in Detail

Bristol-Myers Squibb Company (BMY) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 71.98%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 38.73% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 15.01%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Revenue growth has slowed to just 2.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. The debt-to-equity ratio of 230.97% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valuation in Context

At a PEG of 181.08, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 8.04x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 9.27x is meaningfully below the trailing 16x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Risk Profile

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Bristol-Myers Squibb Company?

Compare top-rated brokers — low fees, trusted providers, fully regulated.